Remdesivir Treatment and its association with Renal and Hepatic Function in Severe COVID-19
The clinical management of advanced COVID-19 often involves antiviral therapies like remdesivir. However, concerns persist regarding its potential impact on organ function, especially the kidneys and liver, in critically ill patients exhibiting high viral loads. A recent analysis investigated the effects of remdesivir on renal and hepatic parameters in a cohort of 114 patients – comprising 55.8% males with a median age of 71 years – confirmed to have detectable viral loads. The study compared these patients to a control group to assess any differential effects of the antiviral treatment.
Renal Function and Remdesivir
Analysis of baseline plasma creatinine (PCr) levels revealed no significant difference in creatinine reduction between the remdesivir and control groups.Patients with initial PCr levels below 150 µmol/l experienced comparable decreases in both groups (-6 µmol/l vs. -8 µmol/l, p = 0.11). Similarly, patients with higher baseline PCr (≥ 150 µmol/l) showed equivalent reductions in creatinine levels following treatment (-57 µmol/l for remdesivir vs. -65 µmol/l for controls,p > 0.9). These findings suggest that remdesivir therapy itself does not independently influence creatinine levels.
Instead, changes in PCr were strongly correlated with pre-existing creatinine levels (p < 0.001), the duration of hospitalization (p < 0.001), and the leukocyte-to-lymphocyte ratio (p = 0.025). This indicates that the severity of illness and pre-existing renal status are more significant determinants of creatinine fluctuations than remdesivir governance. Hepatic function and Remdesivir
While the impact on renal function appeared minimal, the study identified a modest increase in plasma urea (PU) levels within the remdesivir group (1 mmol/l vs. 0 mmol/l in controls, p = 0.009). This increase was statistically linked to remdesivir treatment (p = 0.026),patient age (p = 0.002),baseline PCr (p < 0.001), hospital stay length (p < 0.001), and the need for invasive positive pressure ventilation (IPPV) (p = 0.035). regarding liver function, statistically significant associations with remdesivir therapy were observed specifically for Gamma-glutamyl transferase (GGT) (p = 0.007) and Alkaline Phosphatase (ALP). Further investigation is warranted to fully elucidate the clinical implications of these findings.Implications for Clinical Practice
These results suggest that, while remdesivir might potentially be associated with minor changes in urea and certain liver enzymes, it does not appear to independently worsen renal function in patients with advanced COVID-19. However, careful monitoring of renal and hepatic parameters remains crucial, particularly in elderly patients, those with pre-existing kidney disease, and individuals requiring prolonged hospitalization or ventilatory support. The observed correlations highlight the importance of considering the overall clinical context and pre-existing conditions when interpreting changes in these laboratory values during remdesivir treatment.